Vertex And Merck Neck-To-Neck In HCV Race

Vertex gets priority review for its protease inhibitor weeks after Merck announces its own accelerated timeline.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet